Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data Lars Erik KristensenAtul DeodharDafna D. Gladman Commentary Open access 02 May 2024 Pages: 487 - 499
Neutrophilic Activity Biomarkers (Plasma Neutrophil Extracellular Traps and Calprotectin) in Established Patients with Rheumatoid Arthritis Receiving Biological or JAK Inhibitors: A Clinical and Ultrasonographic Study Beatriz Frade-SosaAndrés PonceRaimon Sanmarti Original Research Open access 02 March 2024 Pages: 501 - 521
Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases Ran JinSilvia KruppertJonathan Kay Original Research Open access 04 March 2024 Pages: 523 - 537
The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study Piero RuscittiGiulia CataldiPaola Cipriani Original Research Open access 04 March 2024 Pages: 539 - 551
Assessment of Patient–Physician Interactions in Psoriatic Arthritis: National Results of the ASSIST Study Fabio Massimo PerrottaRossana ScrivoEnnio Lubrano Original Research Open access 06 March 2024 Pages: 553 - 562
Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study Louis BessetteJonathan ChanDerek Haaland Original Research Open access 11 March 2024 Pages: 563 - 582
Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies Xenofon BaraliakosAnnette E. SzumskiCecilia E. Borlenghi Original Research Open access 15 March 2024 Pages: 583 - 597
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE Roy FleischmannRicardo BlancoEduardo Mysler Original Research Open access 18 March 2024 Pages: 599 - 615
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial Lars Erik KristensenMauro KeisermanFrank Behrens Original Research Open access 18 March 2024 Pages: 617 - 632
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial Andrew ÖstörFilip Van den BoschAlan Kivitz Original Research Open access 18 March 2024 Pages: 633 - 648
Long-Term Efficacy Following Intra-articular Injection of Carboxymethyl-chitosan, a New Product Class for Knee Osteoarthritis: Results from an Observational Study in Germany Nils A. LynenChristoph EichhornWim Weyenberg Original Research Open access 18 March 2024 Pages: 649 - 662
Clinical Characteristics of “Severe” Peripheral Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort Ennio LubranoSilvia ScriffignanoFabio Massimo Perrotta Original Research Open access 09 April 2024 Pages: 663 - 674
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies Alan J. KivitzJoel M. KremerAtul Singhal Original Research Open access 16 April 2024 Pages: 675 - 689
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial Kurt de VlamWalter P. MaksymowychPhilip G. Conaghan Original Research Open access 18 April 2024 Pages: 691 - 707
A Machine Learning Approach for Prediction of CDAI Remission with TNF Inhibitors: A Concept of Precision Medicine from the FIRST Registry Koshiro SonomotoYoshihisa FujinoYoshiya Tanaka Original Research Open access 18 April 2024 Pages: 709 - 736
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials Gerd R. BurmesterJayne StiglerLianne S. Gensler Original Research Open access 29 April 2024 Pages: 737 - 753
A Phase 1a Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7303509, an Anti-TGFβ3 Antibody, in Healthy Volunteers Lyrialle W. HanSamira JamalianSara Glickstein Original Research Open access 25 April 2024 Pages: 755 - 771
Elevating the Standard of Care for Patients with Axial Spondyloarthritis: ‘Calls to Action’ from Rheumacensus, a Multistakeholder Pan-European Initiative Andri PhokaBart J. F. van den BemtXenofon Baraliakos Original Research Open access 25 April 2024 Pages: 773 - 794
Elevating the Standard of Care for Patients with Psoriatic Arthritis: ‘Calls to Action’ from a Multistakeholder Pan-European Initiative Iris VerbinnenEmilio Monte-BoquetPhilip S. Helliwell Original Research Open access 25 April 2024 Pages: 795 - 815
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison Philip J. MeaseRichard B. WarrenIain B. McInnes Brief Report Open access 06 March 2024 Pages: 817 - 828
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison Richard B. WarrenIain B. McInnesPhilip J. Mease Brief Report Open access 15 March 2024 Pages: 829 - 839
Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting Joshua F. BakerCatherine BakewellKarim R. Masri Brief Report Open access 20 March 2024 Pages: 841 - 853
Current Use and Barriers to Point-of-Care Ultrasound in Rheumatology: A National Survey of VA Medical Centers Ayesha IqbalMadiha AhmadNilam J. Soni Brief Report Open access 06 April 2024 Pages: 855 - 867
Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis Patrick BrossardChristian Laveille Brief Report Open access 25 April 2024 Pages: 869 - 880